Combination therapy for treating executive function disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for executive function disorders such as ADHD and autism, particularly those using molecular stimulants like methylphenidate, are associated with significant side effects and develop tolerance over time, leading to short-term efficacy without addressing the underlying causes.
Innovation Solution
A combination therapy of lacosamide and oxcarbazepine, administered in specific dosages, is used to treat executive dysfunction symptoms in a subject in need thereof, wherein the lacosamide is administered to the subject in a combination of lacosamide and oxcarbazepine, administered to the subject in an amount of 100-400 mg/day, and the oxcarbazepine is administered to the subject in an amount of 600-1200 mg/day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If molecular stimulants like methylphenidate are used to treat executive function disorders, then short-term efficacy is achieved, but tolerance develops over time and side effects occur
Solution Approach 1:
The patent changes the pharmacological parameters by switching from stimulant-based treatment (methylphenidate) to a combination of antiepileptic drugs (lacosamide and oxcarbazepine) with different mechanisms of action. This parameter change allows for sustained treatment effectiveness without the tolerance development that characterizes stimulant therapy, as the combination therapy targets multiple neural pathways involved in executive function regulation.
Solution Approach 2:
The patent employs a composite treatment approach by combining two antiepileptic drugs (lacosamide and oxcarbazepine) with complementary mechanisms of action. Lacosamide enhances slow inactivation of voltage-gated sodium channels while oxcarbazepine blocks high-threshold calcium channels, creating a synergistic effect that provides durable treatment effectiveness for executive function disorders without the limitations of monotherapy or stimulant-based approaches.
2Reliability
If molecular stimulants are used to treat executive function disorders, then attention and behavior control are improved, but significant side effects occur including addiction, seizures, and mood disorders
Solution Approach 1:
The patent converts the typically unwanted antiepileptic properties into a beneficial treatment for executive function disorders. By utilizing drugs designed to stabilize abnormal neural firing patterns in epilepsy, the invention achieves stabilization of dysregulated neural circuits in ADHD and autism, converting a treatment for one neurological condition into a beneficial therapy for another with a more favorable side effect profile.
Solution Approach 2:
The patent introduces antiepileptic drugs as intermediary substances that mediate the treatment of executive function disorders through a different physiological pathway than traditional stimulants. Instead of directly stimulating neurotransmitter release or blocking reuptake, lacosamide and oxcarbazepine act as intermediaries that stabilize neuronal excitability and modulate neural network activity, indirectly improving executive function symptoms while avoiding direct stimulation-related side effects.
Data Source
AI summary
The present invention relates to the treatment of an executive function disorder, such as attention deficit hyperactivity disorder (ADHD) and/or autism with both lacosamide and oxcarbazepine.